Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 20/20 | 0.83 |
| ▸ | NEK2 | P51955 | 3/20 | 0.62 |
| ▸ | CSF1R | P07333 | 2/20 | 0.62 |
| ▸ | PIM1 | P11309 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.62 |
| ▸ | STK3 | Q13188 | 2/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.62 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.62 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.62 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.62 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.62 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063355 | 0.93 | PLK1 (0.85) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5062263 | 0.91 | PLK1 (0.70) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL4041917 | 0.91 | PLK1 (1.00) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5067436 | 0.90 | PLK1 (0.80) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5066012 | 0.90 | PLK1 (0.80) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5062393 | 0.89 | PLK1 (0.68) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5067419 | 0.89 | PLK1 (0.68) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5058224 | 0.89 | PLK1 (0.68) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5062494 | 0.89 | PLK1 (0.85) | PLK1NEK2CSF1RPIM1KDR | |
| SCHEMBL5062584 | 0.89 | PLK1 (0.76) | PLK1NEK2CSF1RPIM1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | CYP3A4, TPMT, TYMP | PLK1 193/4885NEK2 2846/4885CSF1R 4003/4885 |
| US-20060074119-A1 | Thiophene compounds | TPMT, ABCB1, CYP3A5 | PLK1 2123/4885NEK2 4031/4885CSF1R 3595/4885 |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ABCB1, TP53, CCNI | PLK1 130/4885NEK2 636/4885CSF1R 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.